Professional profile
Dr Michael Ng, MBBS (Hons), FRANZCR. Michael is an honours graduate of Monash University Medical School. He trained as a radiation oncology registrar at the Peter MacCallum Cancer Centre and spent his fellowship year overseas at the Royal Marsden Hospital, United Kingdom. He spent this year as a clinical-research fellow focusing in prostate cancer, IMRT and active surveillance. He then returned to Australia and worked as a staff specialist at the Peter MacCallum Cancer Centre in head and neck and gastrointestinal cancers.
He won the Varian prize for his research project in conformal radiation therapy and sparing of salivary glands in 2005 in his time as a registrar. He received a merit award for his work on PSA kinetics in prostate cancer from the American Society of Clinical Oncologists Annual Meeting 2007.
Michael was the Chairperson of a TROG national study assessing the clinical effective, safety and costs into using Intensity Modulated Radiation Therapy (IMRT) in anal cancer. He has been the co-chair of the EviQ Radiation Committee for the last 4 years. EviQ (www.eviq.org.au) is resource for health professionals and Michael role was involved in developing radiation therapy guidelines based on evidence. From August 2015 to Nov 2017, he was chair of the EviQ radiotherapy committee.
As of June 2017, Michael is also is a member of the federal government’s Medical Services Advisory Committee (MSAC) Evaluation Sub-committee (ESC). The focus of this committee is to provide advice on the quality, validity and relevance of internal and external assessments for applications being considered by MSAC.
Michael has special interests in advanced radiation therapy treatments. He has been involved in developing protocols for stereotactic radiosurgery, stereotactic body radiation therapy and deep inspiration breath hold radiation therapy. His practice is located at St. Vincent’s Hospital, Ringwood Private Hospital and Epping Medical Centre.
He has interest in research and participates in various clinical trials (ENZARAD). He is principal investigator of prospective trial assessing the impact of PET PSMA scans in the radiation therapy management of post-prostatectomy patients with PSA failure.